Back to Foresite Capital Management VI LLC
Foresite Capital Management VI LLC
Q2 2026 13F filing
Updated 27 days ago23 disclosed positions worth $642.6M
Portfolio value
$642.6M
Total holdings
23
New positions
0
Closed positions
0
Increased
0
Decreased
0
Turnover
—
Filed
2026-08-14
Full holdings
Every line item disclosed in Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | C CGON CG Oncology, Inc. | $168.4M | 2.37M | 26.20% | — |
| 2 | A ALMS ALUMIS INC. | $119.5M | 4.25M | 18.60% | — |
| 3 | S SPTX Seaport Therapeutics, Inc. | $38.7M | 1.78M | 6.01% | — |
| 4 | D DNLI Denali Therapeutics Inc. | $35.9M | 1.40M | 5.59% | — |
| 5 | C CLDX Celldex Therapeutics, Inc. | $32.7M | 879.7K | 5.09% | — |
| 6 | M MGRB AGIOS PHARMACEUTICALS, INC. | $29.1M | 785.0K | 4.53% | — |
| 7 | C CRVS Corvus Pharmaceuticals, Inc. | $27.4M | 1.83M | 4.26% | — |
| 8 | P PBLS Parabilis Medicines, Inc. | $27.3M | 999.0K | 4.26% | — |
| 9 | G GHRS GH Research PLC | $25.3M | 940.5K | 3.93% | — |
| 10 | J JBIO Jade Biosciences, Inc. | $19.7M | 886.7K | 3.07% | — |
| 11 | H HNGE Hinge Health, Inc. | $18.3M | 220.4K | 2.85% | — |
| 12 | K KYMR Kymera Therapeutics, Inc. | $16.8M | 146.3K | 2.61% | — |
| 13 | A ATAI AtaiBeckley Inc. | $14.5M | 2.75M | 2.26% | — |
| 14 | V VSTM Verastem, Inc. | $12M | 3.15M | 1.87% | — |
| 15 | B BEAM Beam Therapeutics Inc. | $11.3M | 330.0K | 1.76% | — |
| 16 | N NERV Minerva Neurosciences, Inc. | $11M | 1.99M | 1.72% | — |
| 17 | A AVBP ArriVent BioPharma, Inc. | $10.5M | 301.3K | 1.63% | — |
| 18 | A AURA Aura Biosciences, Inc. | $9.5M | 1.33M | 1.47% | — |
| 19 | C CRNX Crinetics Pharmaceuticals, Inc. | $7.9M | 212.0K | 1.23% | — |
| 20 | R RACC Research Alliance Corp III | $3.2M | 300.0K | 0.50% | — |
| 21 | Z ZURA Zura Bio Ltd | $2.7M | 450.0K | 0.41% | — |
| 22 | K KLRA Kailera Therapeutics, Inc. | $826K | 37.5K | 0.13% | — |
| 23 | I IRON Disc Medicine, Inc. | $71K | 970 | 0.01% | — |